| Ending the HIV epidemic in the USA: an economic modelling study in six cities B Nosyk, X Zang, E Krebs, B Enns, JE Min, CN Behrends, C Del Rio, ... The Lancet HIV 7 (7), e491-e503, 2020 | 61 | 2020 |
| The impact of localized implementation: determining the cost-effectiveness of HIV prevention and care interventions across six United States cities. NB Krebs E, Zang X, Enns B, Min JE, Behrends CN, Del Rio C, Dombrowski JC ... AIDS 34 (3), 447-458, 2020 | 50 | 2020 |
| Estimated impact of supervised injection facilities on overdose fatalities and healthcare costs in New York City CN Behrends, D Paone, ML Nolan, E Tuazon, SM Murphy, SN Kapadia, ... Journal of substance abuse treatment 106, 79-88, 2019 | 42 | 2019 |
| “Ending the Epidemic” Will Not Happen Without Addressing Racial/Ethnic Disparities in the United States Human Immunodeficiency Virus Epidemic B Nosyk, E Krebs, X Zang, M Piske, B Enns, JE Min, CN Behrends, ... Clinical Infectious Diseases 71 (11), 2968-2971, 2020 | 41 | 2020 |
| Harm Reduction and Health Services provided by Syringe Services Programs in 2019 and subsequent impact of COVID-19 on Services in 2020 CN Behrends, X Lu, GJ Corry, P LaKosky, SM Prohaska, SN Glick, ... Drug and Alcohol Dependence, 109323, 2022 | 38 | 2022 |
| Development and calibration of a dynamic HIV transmission model for 6 US cities X Zang, E Krebs, JE Min, A Pandya, BDL Marshall, BR Schackman, ... Medical Decision Making 40 (1), 3-16, 2020 | 38 | 2020 |
| A Harm Reduction Approach to Treating Opioid Use Disorder in an Independent Primary Care Practice: a Qualitative Study SN Kapadia, JL Griffin, J Waldman, NR Ziebarth, BR Schackman, ... Journal of General Internal Medicine, 1-8, 2021 | 36 | 2021 |
| Cost-effectiveness of hepatitis C screening and treatment linkage intervention in US methadone maintenance treatment programs BR Schackman, S Gutkind, JR Morgan, JA Leff, CN Behrends, ... Drug and alcohol dependence 185, 411-420, 2018 | 35 | 2018 |
| The projected costs and benefits of a supervised injection facility in Seattle, WA, USA JE Hood, CN Behrends, A Irwin, BR Schackman, D Chan, K Hartfield, ... International Journal of Drug Policy 67, 9-18, 2019 | 34 | 2019 |
| Availability of HIV and HCV on-site testing and treatment at syringe service programs in the United States CN Behrends, AV Nugent, DC Des Jarlais, JA Frimpong, DC Perlman, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 79 (2), e76-e78, 2018 | 31 | 2018 |
| Evaluating equity in community-based naloxone access among racial/ethnic groups in Massachusetts S Nolen, X Zang, A Chatterjee, CN Behrends, TC Green, BP Linas, ... Drug and alcohol dependence 241, 109668, 2022 | 28 | 2022 |
| Ending the Epidemic in America Will Not Happen if the Status Quo Continues: Modeled Projections for Human Immunodeficiency Virus Incidence in 6 US Cities B Nosyk, X Zang, E Krebs, JE Min, CN Behrends, C Del Rio, ... Clinical Infectious Diseases 69 (12), 2195-2198, 2019 | 28 | 2019 |
| The Potential Epidemiological Impact of Coronavirus Disease 2019 (COVID-19) on the Human Immunodeficiency Virus (HIV) Epidemic and the Cost-effectiveness of Linked, Opt-out HIV … X Zang, E Krebs, S Chen, M Piske, WS Armstrong, CN Behrends, ... Clinical Infectious Diseases 72 (11), e828-e834, 2021 | 27 | 2021 |
| Targeting community-based naloxone distribution using opioid overdose death rates: A descriptive analysis of naloxone rescue kits and opioid overdose deaths in Massachusetts … X Zang, A Macmadu, MS Krieger, CN Behrends, TC Green, JR Morgan, ... International Journal of Drug Policy 98, 103435, 2021 | 25 | 2021 |
| The potential epidemiological impact of COVID-19 on the HIV/AIDS epidemic and the cost-effectiveness of linked, opt-out HIV testing: a modeling study in six US cities X Zang, E Krebs, S Chen, M Piske, WS Armstrong, CN Behrends, ... Clinical infectious diseases: an official publication of the Infectious …, 2020 | 22 | 2020 |
| Impact of routine opt-out HIV/HCV screening on testing uptake at a syringe services program: An interrupted time series analysis TS Bartholomew, HE Tookes, DP Serota, CN Behrends, DW Forrest, ... International Journal of Drug Policy 84, 102875, 2020 | 21 | 2020 |
| Improving health equity and ending the HIV epidemic in the USA: a distributional cost-effectiveness analysis in six cities AML Quan, C Mah, E Krebs, X Zang, S Chen, K Althoff, W Armstrong, ... The Lancet HIV 8 (9), e581-e590, 2021 | 20 | 2021 |
| Responding to a surge in overdose deaths: perspectives from US syringe services programs MC Frost, EJ Austin, MA Corcorran, ES Briggs, CN Behrends, AM Juarez, ... Harm Reduction Journal 19 (1), 79, 2022 | 18 | 2022 |
| Decreased odds of injection risk behavior associated with direct versus indirect use of syringe exchange: Evidence from Two California Cities CN Behrends, CS Li, DR Gibson Substance use & misuse 52 (9), 1145-1153, 2017 | 16 | 2017 |
| Barriers to engaging people who use drugs in harm reduction services during the COVID-19 pandemic: A mixed methods study of syringe services program perspectives EJ Austin, MA Corcorran, ES Briggs, MC Frost, CN Behrends, AM Juarez, ... International Journal of Drug Policy 109, 103825, 2022 | 14 | 2022 |
